GLOW1 and GLOW2 – Zenkuda achieved meaningful improvement in DRSS, irrespective of disease severity at baseline 9 4.4% 0% 58.0% 76.4% 0% 25% 50% 75% 100% Level 47 Level 53-61 Sham Zenkuda GLOW1: Sham Level ≤47 (n=45); Sham Level ≥53 (n=80); Zenkuda Level ≤47 (n=46); Zenkuda Level ≥53 (n=82). GLOW2: Sham Level ≤47 (n=92); Sham Level 53 -61 (n=33); Zekuda Level ≤47 (n=100); Zenkuda Level 53 -61 (n=30). Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 48 visit window. Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. Proportion of patients with ≥2 -Step improvement in DRSS from Baseline to Week 48, by baseline DRSS 0% 2.2% 22.2% 51.8% 0% 25% 50% 75% 100% Level 47 Level 53 Sham Zenkuda GLOW1 GLOW2 Figure 7